Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer
NCT ID: NCT00743236
Last Updated: 2017-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1 participants
INTERVENTIONAL
2008-08-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase III trial is studying warm ischemia to see how well it works compared with cold ischemia during surgery in treating patients with stage I kidney cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Cold Ischemia Robot-assisted Partial Nephrectomy
NCT07326280
Remote Ischemic Preconditioning in Cardiac Surgery Trial
NCT01071265
Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery
NCT01534364
Relationship Between Postoperative Tempeartive and Acute Kidney Injury
NCT06647771
Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients
NCT01328912
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine the effect of warm ischemia during partial nephrectomy on long-term renal function in patients with solitary stage I renal cortical tumor and normal contralateral kidney.
Secondary
* Determine to what degree the contralateral kidney compensates for the damage inflicted on the operated kidney during surgery.
* Determine the 1-year disease-specific and overall survival of these patients.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients undergo warm ischemia followed by partial nephrectomy.
* Arm II: Patients undergo cold ischemia followed by partial nephrectomy. Blood and urine samples are collected periodically after nephrectomy to assess renal function.
Patients are followed at 1, 3, 6, 9 , and 12 months after nephrectomy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients undergo warm ischemia followed by partial nephrectomy.
warm ischemia procedure
Warm ischemia followed by partial nephrectomy
Arm II
Patients undergo cold ischemia followed by partial nephrectomy.
cold ischemia procedure
Cold ischemia followed by partial nephrectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cold ischemia procedure
Cold ischemia followed by partial nephrectomy
warm ischemia procedure
Warm ischemia followed by partial nephrectomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of solitary renal cortical tumor
* Tumor size ≤ 4 cm
* Candidate for open partial nephrectomy
* Expected ischemia time \< 45 minutes
* Normal renal function, defined as glomerular filtration rate (GFR) \> 60 mL/min
* No evidence of distant metastasis
* No evidence of local invasion of adjacent structures, including the adrenal gland
* No evidence of tumor extension into the renal venous system
* No evidence of ureteral obstruction on MAG-3 renal scan
* No family history of renal cancer
PATIENT CHARACTERISTICS:
* ECOG performance status 0
* Life expectancy \> 5 years
* No prior malignancy, except for non-melanomatous skin cancer
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph A. Pettus, MD
Role: STUDY_CHAIR
Wake Forest University Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange, California, United States
George Washington University Medical Center
Washington D.C., District of Columbia, United States
University of Chicago Cancer Research Center
Chicago, Illinois, United States
NYU Cancer Institute at New York University Medical Center
New York, New York, United States
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, United States
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000612519
Identifier Type: REGISTRY
Identifier Source: secondary_id
NCI-2009-01120
Identifier Type: REGISTRY
Identifier Source: secondary_id
CCCWFU-89108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.